Updated: August 9, 2007
Autologous CD-20 Targeted T-Cell Therapy
Clinical Trial at the Hutch Now to Recruit CLL Patients
Trained Killer T-Cells to the Rescue
Another interesting clinical trial will soon be open to CLL patients. T-cells collected from patients are grown into large armies and targeted to kill only cells with the CD-20 marker. These activated and targeted killer T-cells will be used in the clean-up of minimum residual disease left after more traditional therapies. This innovative approach is the basis for a Phase I clinical trial at the Fred Hutchinson Cancer Research Center in Seattle. Read our review of this latest evolution in using CTLs in Autologous CD-20 Targeted T-Cell Therapy.
Killer T-Cells and the Risks of CTL Therapies
How T Cells Kill - Serial Killers Up Close and Personal
Cartooning Cellular Mayhem
Whether they are your own home-grown natural variety, or the high-tech armies grown for you outside your body in a research lab, activated T-cells primed for killing their targets are an important line of defense against cancer cells, pathogens and cells infected by viruses. Activated T-cells are called Cytotoxic T Lymphocytes (CTLs) and they are quite different from naïve T-cells prior to their call-up for active duty. We consider how CTLs kill target cells and learn a little bit about why sometimes they fail to complete their mission in Killer T-Cells and the Risks of CTL Therapies.
T-cell Therapy at UCSD
A Start-up Takes an Interesting Approach
The Story of Xcyte and Its Technology
A few years ago, a Seattle start-up called Xcyte Therapies, Inc. developed a technology for ex-vivo activation and expansion of T-cells, in the hope that these externally grown armies of T-cells would prove effective against CLL and lymphoma. The company raised some money from eager venture backers and launched a phase I/II clinical trial of its ‘Xcellerated’ T-cell technology at a number of centers, including UCSD. We were able to track how patients did on this trial. In this article, T-cell Therapy at UCSD, we report on the technology behind this effort.
Is This a Way to Spell C-U-R-E?
Combining Bispecific Antibody and CTL Therapy
While a stem cell transplant is the only process known to produce an actual cure in CLL, immunotherapy is getting more sophisticated. In Combining Bispecific Antibody and CTL Therapy, we explore ideas in active immunotherapy which in combination might point the way to a cure.
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright © 2002-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.